In this study, although CCDC181 failed to discriminate between BPH and PCa patients, the remaining biomarkers exhibited gradually increasing numbers of methylated DNA fragments/mL for healthy individuals, BPH patients, and PCa patients. This evidence concerns the gene CCDC181 and benign prostatic hyperplasia.